EB Research Partnership Australia raises funds to invest in innovative research across the globe to cure Epidermolysis Bullosa as quickly and efficiently as possible.


Grant applications are processed through EB Research Partnership USA and are open biannually, in January and July. We award funding on the advice of the independent Scientific Advisory Board to competitive and innovative research projects with the potential to lead to commercially feasible products and therapies to treat and cure EB.

For a full list of past projects funded visit: 


FIBRX Tissue Repair ​​​Development of Human Recombinant Decorin Core Protein as a Topical Anti-Scarring Therapy for Dystrophic Epidermolysis Bullosa Jean Tang MD PhD ​$300,000
University of Minnesota Next Generation Genome Editing for RDEB Jakub Tolar MD PhD $1,000,000
Tufts Medical Center Development of a Collagen VII Eye Drop for the Treatment of Ocular Disease in Recessive Dystrophic Epidermolysis Bullosa Vicki M Chen MD $336,315
Stanford University Randomized Controlled Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients with Epidermolysis Bullosa

​​Albert Chiou MD          Jean Tang MD PhD


​​​University of South Australia Development of a systemic antibody therapy for the treatment of Epidermolysis Bullosa ​​Alison Cowin PhD ​​​$120,795
Stanford University ​​​​Evaluating the Natural History of Recessive Dystrophic Epidermolysis Bullosa Wounds Jean Tang MD PhD ​​​$498,023
Stanford University EBCRC version 2.0: Investigator and patient portals on Amazon Web Services Jean Tang MD PhD ​​​​$324,382
INSERM Strategies for efficient and long-term engraftment of Mesenchymal Stromal Cells for the treatment of Recessive Dystrophic Epidermolysis Bullosa ​​Alain Hovnanian MD PhD ​​​​$144,351
​​Stanford University ​​An Anonymous Online International Survey of Prevalence and Impact of Cannabinoid Use in Patients with Epidermolysis Bullosa

​​Jean Tang MD PhD             Emily S Gorell DO MS


Stanford University ​​Bridge Funding for iPS Cell Consortium Tony Oro MD PhD ​​$800,000
Amazon Web Services ​​EBRP X AWS Investigator and Patient Data Platform Jean Tang MD PhD ​​$406,000
Thomas Jefferson University Targeting fibrosis for RDEB therapy in preclinical animal models Andrew South PhD ​​$101,350
University of Freiburg Characterization of Tissue Biomarkers for Fibrosis and Inflammation in Patients with Dystrophic Epidermolysis Bullosa Dimitra Kiritsi MD ​​$73,522
King’s College London, University of California, San Francisco Investigating the transcriptome of EB wounds at single-cell level Alexandros Onoufriadis PhD
John McGrath MD
Raymond Cho MD PhD
​Jeffrey Cheung MD
​​Northwestern University, University of Freibug ​​Augmented intelligence in EB: Using deep learning for early detection of squamous cell carcinoma in EB ​​Amy Paller MD, Antonia Reimer-Taschenbrecker MD ​​​$379,267
​​Wings Therapeutics Clinical Development of QR-313 for treatment of DEB ​​Mark De Souza PhD ​​$1,000,000
​​University of Minnesota  Autologous Revertant Mosaic Fibroblasts for Wound Healing in Dystrophic Epidermolysis Bullosa ​​Jakub Tolar MD PhD ​​$1,000,000